Kotak Offshore reduced its stake in IPCA Laboratories from 1.19% to 1.14% by selling 114,115 shares. The value of the sold shares was approximately ₹21.9 Cr at ₹1920.40 apiece.
A pharmaceutical manufacturer and marketer, Ipca Labs produces a wide range of medicines across therapeutic areas including antimalarials, anti-infectives, gastrointestinal treatments, and gynecological formulations. The company operates manufacturing facilities across India and exports its products to international markets. Its distinctive strength lies in its expertise in complex drug formulations, established distribution networks across Indian states, and a focus on affordable healthcare solutions for domestic and global markets.
India FPI activity attributed to Kotak Mahindra group affiliates and offshore funds investing in listed Indian equities.